ArticleScientific reports2025
CRISPR.BOT an autonomous platform for streamlined genetic engineering and molecular biology applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
In the realm of synthetic biology, the pursuit of streamlined experimental processes has given rise to innovative technologies poised to redefine research paradigms. Traditional workflows, laden with laborious and error-prone stages, incur prolonged timelines and escalating costs. Autonomous liquid processing systems emerge as promising tools, holding the potential to enhance precision and efficiency. Yet, the adoption of fully automated systems is impeded by prohibitive costs and maintenance expenses. This study introduces the CRISPR.BOT as a transformative solution, a pioneering autonomous genetic engineering platform designed to revolutionize molecular biology practices. The CRISPR.BOT demonstrates its prowess through a series of pivotal experiments, ranging from the efficient transfer of green fluorescent protein (GFP) encoding plasmid DNA into bacterial hosts to intricate manipulations involving lentiviral transduction and CRISPR-Cas9-mediated genetic editing in human cell lines. Notably, the CRISPR.BOT achieves exceptional results in single-cell subcloning, yielding GFP + CRISPR-gRNA + cells with unprecedented purity levels of 90-100%. Moreover, this study underscores the CRISPR.BOT's potential to facilitate safe genetic engineering practices, enabling researchers to work with pathogenic microorganisms like the SARS CoV-2 virus without direct human contact. An exploration into the cost-effectiveness of LEGO Mindstorms robots reveals their suitability for daily laboratory routines, presenting a cost reduction of up to tenfold compared to commercial alternatives. In conclusion, the CRISPR.BOT emerges as a transformative force in synthetic biology, offering a pathway to redefine experimental processes, enhance precision, and unlock new possibilities in genetic engineering. This research marks a paradigm shift where automation and innovation converge, empowering researchers to navigate uncharted territories with confidence and efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.